Diagnostics, Diagnosis Technology Offers

Vilnius University posted this:

Technology for Contactless Dosimetry / Fluxmetry of Ionising Radiations Vilnius University offers a contactless and in situ continuous dosimetry / fluxmetry system for ionizing radiation detection. A single device measures a very wide range or radiation and is suitable for large area radiation control in radiation research centres, nuclear energy related facilities and specific medical purposes.

CNIC (TTO) posted this:
Technology Transfer Office at Spanish National Center for Cardiovascular Research (CNIC)

New method for the diagnosis of atherosclerosis Inflammation is an active driver of atherosclerotic plaque development and a risk factor for atherosclerotic events. It is therefore of utmost importance to understand the mechanisms behind these inflammatory processes and to be able to develop new diagnostics and treatment modalities for atherosclerotic disorders. CNIC, FJD (Fundación Jiménez Díaz) and UAM (Universidad Autónoma de Madrid) researchers conducted a study to identify new antibodies that show reactivity against the atherosclerotic plaque. They have found that one of these antibodies recognizes a mitochondrial dehydrogenase of the proline metabolism (PRODH). The levels of this protein are increased in the plasma of atherosclerotic mice and humans with carotid disease, supporting the potential use of this PRODH as a biomarker for atherosclerosis.

Covid-19 Innovation Challenges by Innoget posted this:

Viral RNA-dependent RNA Polymerases Viral RNA-dependent RNA Polymerases (RdRPs) Targeted Library (1259 compounds) with predicted activity against viral RdRPs is offered. It has been carefully designed using machine learning (artificial neural networks and Bayesian statistics

Covid-19 Innovation Challenges by Innoget posted this:

SARS-CoV-2 NSP16 Targeted Library SARS-CoV-2 2′-O-methyltransferase (NSP16) Targeted Library, which contains 1049 compounds with predicted activity against SARS-CoV-2 NSP16 is offered. The library has been designed with receptor-based virtual screening using crystal structure of SARS-CoV-2 2′-O-MTase (PDB ID: 6WKQ).

Covid-19 Innovation Challenges by Innoget posted this:

SARS-CoV-2 Helicase Targeted Library The offer SARS-CoV-2 Helicase (NSP13) Targeted Library, which contain 1170 compounds with predicted activity against this vital protein. The overall procedure included accurate flexible docking of Drug-like Green Collection into helicase active site.

CNIC (TTO) posted this:
Technology Transfer Office at Spanish National Center for Cardiovascular Research (CNIC)

Antibodies for the diagnosis and/or treatment of atherosclerosis Novel atherosclerosis biomarkers are in need to improve the strategies for diagnosis and prognosis of cardiovascular disease. CNIC and DKFZ researchers have discovered 18 novel antibodies that show reactivity against the atherosclerotic plaque, which can thus be potentially used for the diagnosis of this disease. Moreover, the use of one such antibody, A12, delays the progression of atherosclerosis and reduces the level of free circulating cholesterol and LDL.

CNIC (TTO) posted this:
Technology Transfer Office at Spanish National Center for Cardiovascular Research (CNIC)

A new therapy for the treatment of myeloproliferative diseases Myelodysplastic/myeloproliferative neoplasms (MPN) are a group of diseases that affect normal blood cell production in the bone marrow. In this case the bone marrow causes an overproduction of one or more blood cell types (red cells, white cells or platelets). Complications arise over time due to the abnormally high number of blood cells that accumulate in the bone marrow and in the circulating blood. In many cases, these diseases develop slowly and get worse gradually. In some cases, MPN can progress to leukemia. Compounds capable of preventing and treating these types of diseases are urgently needed. CNIC researchers have identified new therapeutic targets based on alterations in the regulation of mesenchymal stem cells (MSC) in the hematopoietic niche by sympathetic nerves. They have also defined an in vitro method for prognosis/diagnosis of MPNs and/or to define the disease´s stage, and a method to screen for therapeutic compounds useful to treat MPNs.

CNIC (TTO) posted this:
Technology Transfer Office at Spanish National Center for Cardiovascular Research (CNIC)

New microRNAs for the diagnosis of cardiomyopathies Inflammation in the myocardium or myocarditis is a disease with heterogeneous aetiology, frequently caused by an infectious pathogen, toxins, drugs or by an autoimmune disorder. Its clinical variability and its nonspecific symptoms make the diagnosis of myocarditis a process that is not always easy. There is an urgent need for accurate, fast point-of-care tests that simultaneously provide diagnostic and prognostic information about a patient entering the hospital with symptoms of acute heart failure. CNIC researchers have identified the role of an specific miRNA in cardiomyopathies processes and have studied the differential expression in blood plasma of patients compared with healthy subjects. These miRNAs can be used as biomarker to improve the diagnosis of acute myocarditis.

CNIC (TTO) posted this:
Technology Transfer Office at Spanish National Center for Cardiovascular Research (CNIC)

SHIP-1 inhibitors for prophylactic treatment and/or prevention of infectious diseases Trained immunity can be defined as a defacto innate immune memory that induces enhanced inflammatory and antimicrobial properties in innate immune cells. Innate immune cells can be trained to exhibit an enhanced and lasting response to subsequent infections with microbial components. Importantly, this boosted response can be triggered against pathogens diverse from those that induce the training. However, improving the heterologous response of trained innate immune cells remains complicated. CNIC, Syracuse University and SUNY Upstate Medical University researchers have discovered that the use of SHIP-1 inhibitors, enhance the non-specific response of trained innate immune cells. This increased activity may offer an improved prophylactic treatment or prevention of subsequent infections.

Jorian Bos posted this:
Other at EIT Digital

SIDEKICK HEALTH - Therapeutics platform to prevent chronic diseases Lifestyle and treatment support powered by data science and A.I. Digital therapies designed for life. Our gamified programs help improve health outcomes, create connections with clinicians and patients, and deliver data insights.

Covid-19 Innovation Challenges by Innoget posted this:

Rapid Computational Screening of Natural Products for COVID-19 Anti-Viral Agents Some edible compounds are potent antiviral agents and were tested successfully against SARS and MERS viruses. They hence provide an large source for rapid development and production of cure against COVID-19. These compounds are commercially available, and are generally recognized as safe (GRAS), with a vast chemical diversity. Despite the high-level genetic similarity to other coronaviruses, such as SARS-CoV and MERS-CoV, recent works demonstrate major structural differences in SARS-CoV2 (the causal agent of COVID-19 disease) proteins. The need for specific anti-SARS-COV2 treatments is acute. Rapid screening of the food derived compounds, using chemoinformatic modeling tools that are common in our lab, allow the identification of a small number of potent antiviral candidate inhibitors of recent published SARS-CoV2 target proteins. Project ID : 47-2020-10884

Covid-19 Innovation Challenges by Innoget posted this:

Plant-based Diagnostic Kit to Detect Sick and Recovered SARS-CoV-2 Virus Patients Genetically modified plant systems that allow identification of SARS-CoV-2 RNA and anti-SARS-CoV-2 antibodies Applications Preventing the spread of the epidemic Restoring economic activity by returning immune-positive, symptomless people to work Features System can be rapidly reproduced through seeds Essentially unlimited quantities, extremely inexpensive Can be used in any environment No need for special machinery Adaptable to other diseases Project ID : 47-2020-10883

Covid-19 Innovation Challenges by Innoget posted this:

Using Peptide Nucleic Acids (PNAs) as a Tool to Diagnose COVID-19 Using Peptide Nucleic Acids (PNAs) as a Tool to Diagnose COVID-19 We offer a fast and efficient diagnostic method which can be applied to a large amount of tests in a short time. Our method is based on a kit which identifies specifically the viral RNA biomarker. The test is characterized by reliability, sensitivity, rapid (not more than 10-15 minutes), low toxicity and reasonable cost. Project ID : 47-2020-10881

Yissum - Research Development Company of the Hebrew University posted this:

Rapid Computational Screening of Natural Products for COVID-19 Anti-Viral Agents Some edible compounds are potent antiviral agents and were tested successfully against SARS and MERS viruses. They hence provide an large source for rapid development and production of cure against COVID-19. These compounds are commercially available, and are generally recognized as safe (GRAS), with a vast chemical diversity. Despite the high-level genetic similarity to other coronaviruses, such as SARS-CoV and MERS-CoV, recent works demonstrate major structural differences in SARS-CoV2 (the causal agent of COVID-19 disease) proteins. The need for specific anti-SARS-COV2 treatments is acute. Rapid screening of the food derived compounds, using chemoinformatic modeling tools that are common in our lab, allow the identification of a small number of potent antiviral candidate inhibitors of recent published SARS-CoV2 target proteins. Project ID : 47-2020-10884

Yissum - Research Development Company of the Hebrew University posted this:

Using Peptide Nucleic Acids (PNAs) as a Tool to Diagnose COVID-19 Using Peptide Nucleic Acids (PNAs) as a Tool to Diagnose COVID-19 Project ID : 47-2020-10881

Diagnostics, Diagnosis Technology Offers

Innovation Resources

Sitemaps

Support

Company

Top Posts Categories

Recognitions

Diagnostics, Diagnosis Technology Offers

Recognitions

Follow us